Summit Therapeutics’ Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint – Summit Therapeutics (NASDAQ:SMMT)
Summit Therapeutics Inc. SMMT released topline results on Friday from the Phase 3 HARMONi trial of ivonescimab plus platinum-doublet…